WallStreetZenWallStreetZen

NASDAQ: RNAZ
Transcode Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their RNAZ stock forecasts and price targets.

Forecast return on equity

Is RNAZ forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is RNAZ forecast to generate an efficient return on assets?

Company
-2.74%
Industry
-16.73%
RNAZ is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RNAZ earnings per share forecast

What is RNAZ's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.33
Avg 2 year Forecast
-$0.24

RNAZ revenue forecast

What is RNAZ's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$510.0k
Avg 2 year Forecast
$0.0

RNAZ vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNAZ$1.65N/AN/A
ESLA$0.64N/AN/A
IGC$0.28$6.00+2,073.91%Buy
QNCX$28.59$77.33+170.49%Strong Buy
CVM$1.52N/AN/A
View Top Biotech Stocks

Transcode Therapeutics Stock Forecast FAQ

What is RNAZ's earnings growth forecast for 2026-2027?

(NASDAQ: RNAZ) Transcode Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 23.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,202.66%.

Transcode Therapeutics's earnings in 2026 is -$46,284,811.On average, 3 Wall Street analysts forecast RNAZ's earnings for 2026 to be -$5,526,193, with the lowest RNAZ earnings forecast at -$5,309,480, and the highest RNAZ earnings forecast at -$5,688,728.

In 2027, RNAZ is forecast to generate -$4,144,645 in earnings, with the lowest earnings forecast at -$3,982,110 and the highest earnings forecast at -$4,266,546.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.

What is RNAZ's revenue growth forecast for 2026-2027?

(NASDAQ: RNAZ) Transcode Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 11.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 18.69%.

Transcode Therapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast RNAZ's revenue for 2026 to be $8,634,677, with the lowest RNAZ revenue forecast at $8,296,062, and the highest RNAZ revenue forecast at $8,888,638.

In 2027, RNAZ is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is RNAZ's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: RNAZ) forecast ROA is -2.74%, which is higher than the forecast US Biotechnology industry average of -16.73%.

What is RNAZ's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: RNAZ) Transcode Therapeutics's current Earnings Per Share (EPS) is -$52.37. On average, analysts forecast that RNAZ's EPS will be -$0.33 for 2026, with the lowest EPS forecast at -$0.31, and the highest EPS forecast at -$0.34. In 2027, RNAZ's EPS is forecast to hit -$0.24 (min: -$0.24, max: -$0.25).

What is RNAZ's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: RNAZ) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.